X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-18 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.99 | -54,728 | 4,428,587 | -1% | -$109,159 | |||||
| D | 2025-08-18 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $43.98 | -10,000 | 93,466 | -10% | -$439,776 | |||||
| M | 2025-08-18 | MDGL | Madrigal Pharmaceuticals, Inc. | Baker Bros. Advisors LP | Dir | P - Purchase | $380.58 | +97,065 | 1,947,968 | +5% | +$36,941,197 | |||||
2025-08-18 | MDGL | Madrigal Pharmaceuticals, Inc. | Baker Bros. Advisors LP | Dir | P - Purchase | $364.04 | +68,618 | 1,859,091 | +4% | +$24,979,827 | ||||||
| M | 2025-08-19 | ETON | Eton Pharmaceuticals, Inc. | Gruber James R. | CFO | S - Sale | $16.15 | -41,713 | 204,753 | -17% | -$673,714 | |||||
| DM | 2025-08-18 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.18 | -4,304 | 0 | -100% | -$22,284 | |||||
| M | 2025-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.04 | -1,060 | 55,924 | -2% | -$3,224 | |||||
| M | 2025-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Schwartz Jonathan David | See Remarks | S - Sale | $3.04 | -2,485 | 221,609 | -1% | -$7,561 | |||||
| M | 2025-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.04 | -1,592 | 135,462 | -1% | -$4,839 | |||||
| D | 2025-08-18 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale+OE | $38.21 | -16,389 | 103,613 | -14% | -$626,171 | |||||
2025-08-18 | ANIP | Ani Pharmaceuticals Inc | Thoma Jeanne | Dir | S - Sale | $89.15 | -21,540 | 23,405 | -48% | -$1,920,370 | ||||||
2025-08-20 | ANIP | Ani Pharmaceuticals Inc | Pera Antonio R | Dir | S - Sale | $89.73 | -5,421 | 29,952 | -15% | -$486,426 | ||||||
2025-08-19 | ZVRA | Zevra Therapeutics, Inc. | Bode John B | Dir | P - Purchase | $9.17 | +5,000 | 45,000 | +13% | +$45,825 | ||||||
| D | 2025-08-18 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $33.77 | -16,200 | 40,215 | -29% | -$547,141 | |||||
| M | 2025-08-18 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $20.02 | -10,983 | 929,409 | -1% | -$219,906 | |||||
| D | 2025-08-18 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $128.40 | -6,865 | 588,335 | -1% | -$881,470 | |||||
2025-08-20 | TNXP | Tonix Pharmaceuticals Holding Corp. | Treco James | Dir | P - Purchase | $36.00 | +250 | 250 | New | +$9,000 | ||||||
2025-08-18 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $18.24 | -2,805 | 23,970 | -10% | -$51,158 | ||||||
2025-08-18 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale | $18.24 | -12,126 | 153,470 | -7% | -$221,154 | ||||||
2025-08-18 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $18.24 | -1,683 | 23,948 | -7% | -$30,695 | ||||||
2025-08-19 | GOSS | Gossamer Bio, Inc. | Milligan Sandra | Dir | P - Purchase | $1.92 | +26,050 | 58,050 | +81% | +$50,016 | ||||||
2025-08-18 | ALXO | Alx Oncology Holdings Inc | Shantharam Harish | CFO | P - Purchase | $0.78 | +75,000 | 75,000 | New | +$58,403 | ||||||
| A | 2025-08-15 | ARCT | Arcturus Therapeutics Holdings Inc. | Sassine Andy | CFO | P - Purchase | $16.56 | +1,238 | 221,764 | +1% | +$20,499 | |||||
| A | 2025-08-18 | PRGO | Perrigo Co Plc | Parker Geoffrey M. | Dir | P - Purchase | $22.97 | +4,375 | 64,666 | +7% | +$100,497 | |||||
| D | 2025-08-15 | WVE | Wave Life Sciences Ltd. | Tan Aik Na | Dir | S - Sale+OE | $9.25 | -21,000 | 40,388 | -34% | -$194,250 | |||||
2025-08-18 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $50.23 | -17,353 | 463,318 | -4% | -$871,722 | ||||||
| D | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO | S - Sale+OE | $6.77 | -4,106 | 278,000 | -1% | -$27,786 | |||||
| D | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC, Secretary | S - Sale+OE | $6.77 | -4,365 | 54,858 | -7% | -$29,538 | |||||
| D | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $6.77 | -16,058 | 1,770,203 | -1% | -$108,666 | |||||
| D | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Chief Commercial Officer | S - Sale+OE | $6.77 | -3,766 | 41,931 | -8% | -$25,485 | |||||
2025-08-18 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale | $25.18 | -22,000 | 40,130 | -35% | -$554,024 | ||||||
| M | 2025-08-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $455.89 | -2,851 | 20,902 | -12% | -$1,299,746 | |||||
2025-08-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $453.27 | -1,396 | 29,466 | -5% | -$632,759 | ||||||
2025-08-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $453.27 | -2,274 | 50,178 | -4% | -$1,030,727 | ||||||
2025-08-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $453.27 | -6,979 | 56,628 | -11% | -$3,163,346 | ||||||
2025-08-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $453.27 | -1,396 | 23,256 | -6% | -$632,759 | ||||||
| D | 2025-08-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Bonney Michael W | Dir | S - Sale+OE | $450.00 | -11,250 | 20,804 | -35% | -$5,062,500 | |||||
| D | 2025-08-15 | COLL | Collegium Pharmaceutical, Inc | Santini Gino | Dir | S - Sale+OE | $37.19 | -5,405 | 95,042 | -5% | -$201,018 | |||||
2025-08-18 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $27.80 | -5,000 | 203,866 | -2% | -$139,000 | ||||||
| D | 2025-08-18 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $36.24 | -6,641 | 76,604 | -8% | -$240,643 | |||||
| D | 2025-08-18 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $36.24 | -1,883 | 42,065 | -4% | -$68,232 | |||||
| D | 2025-08-19 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $38.31 | -2,000 | 140,610 | -1% | -$76,620 | |||||
| D | 2025-08-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $75.42 | -27,000 | 249,062 | -10% | -$2,036,325 | |||||
2025-08-15 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $26.18 | -20,000 | 356,412 | -5% | -$523,674 | ||||||
| D | 2025-08-15 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $48.58 | -2,813 | 103,901 | -3% | -$136,656 | |||||
| D | 2025-08-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale+OE | $13.19 | -2,649 | 129,493 | -2% | -$34,932 | |||||
| D | 2025-08-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $13.19 | -2,939 | 116,533 | -2% | -$38,757 | |||||
| D | 2025-08-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $13.19 | -4,409 | 374,548 | -1% | -$58,141 | |||||
2025-08-15 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale | $36.50 | -21,573 | 0 | -100% | -$787,378 | ||||||
2025-08-15 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $0.64 | -611 | 89,198 | -1% | -$391 | ||||||
2025-08-15 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | CEO | S - Sale | $0.64 | -2,382 | 212,888 | -1% | -$1,525 | ||||||
| D | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $16.65 | -217 | 10,609 | -2% | -$3,613 | |||||
| D | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $16.65 | -76 | 7,455 | -1% | -$1,265 | |||||
| D | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $16.65 | -73 | 4,548 | -2% | -$1,215 | |||||
| D | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $16.65 | -59 | 5,215 | -1% | -$982 | |||||
2025-08-15 | ARCT | Arcturus Therapeutics Holdings Inc. | Sassine Andy | CFO | P - Purchase | $16.56 | +1,238 | 221,764 | +1% | +$20,499 | ||||||
2025-08-15 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $2.90 | +5,076 | 1,018,986 | +1% | +$14,709 | ||||||
2025-08-18 | PRGO | Perrigo Co Plc | Parker Geoffrey M. | Dir | P - Purchase | $22.97 | +4,375 | 64,666 | +7% | +$100,497 | ||||||
2025-08-18 | PRGO | Perrigo Co Plc | Bezerra Eduardo Guarita | EVP, CFO | P - Purchase | $22.74 | +3,000 | 48,949 | +7% | +$68,207 | ||||||
| D | 2025-08-15 | JNJ | Johnson & Johnson | Wolk Joseph J | EVP, CFO | S - Sale+OE | $176.91 | -16,820 | 84,980 | -17% | -$2,975,571 | |||||
2025-08-14 | ATAI | Atai Life Sciences N.V. | Apeiron Investment Group Ltd. | 10% | P - Purchase | $2.19 | +8,675,799 | 52,844,516 | +20% | +$19,000,000 | ||||||
2025-08-18 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $367.81 | -1,304 | 9,173 | -12% | -$479,627 | ||||||
2025-08-18 | ANIP | Ani Pharmaceuticals Inc | Leonard Matthew J | Dir | S - Sale | $88.17 | -6,937 | 9,392 | -42% | -$611,635 | ||||||
2025-08-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $15.00 | -8,500 | 426,642 | -2% | -$127,466 | ||||||
| DM | 2025-08-14 | SNDX | Syndax Pharmaceuticals Inc | Podlesak Dennis | Dir | S - Sale+OE | $15.19 | -57,600 | 191,763 | -23% | -$875,100 | |||||
2025-08-14 | RCKT | Rocket Pharmaceuticals, Inc. | Schwartz Jonathan David | See Remarks | S - Sale | $3.02 | -11,161 | 224,094 | -5% | -$33,695 | ||||||
2025-08-14 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.02 | -7,043 | 56,984 | -11% | -$21,263 | ||||||
2025-08-14 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.02 | -12,109 | 137,054 | -8% | -$36,557 | ||||||
2025-08-15 | ANIP | Ani Pharmaceuticals Inc | Walsh Patrick D | Dir | S - Sale | $89.05 | -9,000 | 70,048 | -11% | -$801,450 | ||||||
2025-08-15 | EBS | Emergent Biosolutions Inc. | Zoon Kathryn C | Dir | S - Sale | $8.87 | -7,086 | 71,799 | -9% | -$62,853 | ||||||
| M | 2025-08-14 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $88.25 | -100,000 | 629,508 | -14% | -$8,824,533 | |||||
2025-08-14 | SUPN | Supernus Pharmaceuticals, Inc. | Sensenig Bethany | Dir | S - Sale | $42.25 | -5,369 | 0 | -100% | -$226,840 | ||||||
| D | 2025-08-15 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $35.42 | -1,438 | 16,720 | -8% | -$50,932 | |||||
2025-08-15 | ANIP | Ani Pharmaceuticals Inc | Gassert Chad | SVP - CORP. DEV., STRATEGY | S - Sale | $86.97 | -20,000 | 246,841 | -7% | -$1,739,400 | ||||||
2025-08-14 | SUPN | Supernus Pharmaceuticals, Inc. | Hudson Frederick M. | Dir | S - Sale | $42.26 | -7,457 | 46,307 | -14% | -$315,133 | ||||||
2025-08-15 | EOLS | Evolus, Inc. | Stewart Brady | Dir | P - Purchase | $6.82 | +30,000 | 88,629 | +51% | +$204,486 | ||||||
2025-08-14 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale | $127.34 | -10,000 | 79,764 | -11% | -$1,273,363 | ||||||
| M | 2025-08-14 | CALC | Calcimedica, Inc. | Hebbar Sudarshan | Chief Medical Officer | P - Purchase | $2.74 | +5,976 | 51,976 | +13% | +$16,361 | |||||
| M | 2025-08-13 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $61.11 | -32,174 | 1,064,457 | -3% | -$1,966,286 | |||||
| M | 2025-08-14 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $2.00 | -4,900 | 4,483,315 | 0% | -$9,800 | |||||
| D | 2025-08-15 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $17.23 | -6,000 | 110,886 | -5% | -$103,380 | |||||
| D | 2025-08-15 | MDGL | Madrigal Pharmaceuticals, Inc. | Bate Kenneth | Dir | S - Sale+OE | $365.20 | -10,000 | 2,627 | -79% | -$3,652,009 | |||||
| M | 2025-08-13 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $20.00 | -10,000 | 262,122 | -4% | -$200,000 | |||||
| D | 2025-08-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale+OE | $46.56 | -10,000 | 97,130 | -9% | -$465,632 | |||||
| D | 2025-08-13 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale+OE | $38.03 | -4,861 | 103,613 | -4% | -$184,881 | |||||
2025-08-13 | XERS | Xeris Biopharma Holdings, Inc. | Johnson John | Dir | S - Sale | $7.32 | -107,500 | 833,483 | -11% | -$786,459 | ||||||
| DM | 2025-08-13 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale+OE | $304.56 | -89,794 | 1,244,693 | -7% | -$27,347,635 | |||||
| D | 2025-08-13 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $300.45 | -11,013 | 252,018 | -4% | -$3,308,877 | |||||
2025-08-14 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale | $9.29 | -71,694 | 267,235 | -21% | -$666,037 | ||||||
2025-08-13 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $15.00 | -13,712 | 19,631 | -41% | -$205,680 | ||||||
2025-08-14 | ABEO | Abeona Therapeutics Inc. | Crombez Eric | Dir | S - Sale | $6.93 | -4,718 | 42,427 | -10% | -$32,683 | ||||||
2025-08-15 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $7.36 | -15,000 | 462,666 | -3% | -$110,358 | ||||||
| M | 2025-08-13 | AMRX | Amneal Pharmaceuticals, Inc. | Konidaris Tasos | EVP, CFO | S - Sale | $9.33 | -499,730 | 122,152 | -80% | -$4,663,070 | |||||
2025-08-15 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $38.42 | -5,000 | 387,274 | -1% | -$192,100 | ||||||
2025-08-15 | LLY | Eli Lilly & Co | Montarce Lucas | EVP, CFO | P - Purchase | $691.79 | +715 | 14,685 | +5% | +$494,627 | ||||||
2025-08-13 | COLL | Collegium Pharmaceutical, Inc | Rubric Capital Management LP | 10% | S - Sale | $37.85 | -25,000 | 3,132,743 | -1% | -$946,250 | ||||||
2025-08-13 | ALDX | Aldeyra Therapeutics, Inc. | Alfieri Michael | Principal Financial Officer | P - Purchase | $5.30 | +2,500 | 2,500 | New | +$13,250 | ||||||
2025-08-06 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale | $42.73 | -30,914 | 65,806 | -32% | -$1,320,844 | ||||||
| D | 2025-08-13 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $46.66 | -1,542 | 38,867 | -4% | -$71,950 | |||||
| D | 2025-08-14 | ALNY | Alnylam Pharmaceuticals, Inc. | Ausiello Dennis A | Dir | S - Sale+OE | $436.58 | -31,448 | 4,411 | -88% | -$13,729,536 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |